Association of lipoprotein‐associated phospholipase A2 mass with asymptomatic cerebral artery stenosis

Youxin Wang, Bin Zhou, Pingan Zhou, Yan Yao, Qinghua Cui, Yingping Liu, Jichun Yang, Shouling Wu, Xingquan Zhao, Yong ZhouJournal of Cellular and Molecular Medicine 2018 · DOI

TL;DR

This study investigates the link between Lp-PLA2 mass, a marker of inflammation, and asymptomatic cerebral artery stenosis (ACAS) in a Chinese population. They found that higher Lp-PLA2 levels are associated with an increased risk of ACAS, particularly in men and older individuals, suggesting Lp-PLA2 could be a useful biomarker for early detection of stroke risk.

What Problem Does This Paper Address?

Ischemic stroke is a major cause of death and disability worldwide, and cerebral artery stenosis (CAS) is a significant contributor. Identifying individuals at risk for stroke, especially those with asymptomatic stenosis, is crucial for timely intervention. While lipoprotein-associated phospholipase A2 (Lp-PLA2) has been implicated in atherosclerosis, its role in asymptomatic cerebral artery stenosis has been inconsistent across studies, possibly due to differing populations and methodologies. This paper aims to clarify this association in a large cohort of asymptomatic North Chinese adults, exploring Lp-PLA2 as a potential biomarker for early detection of subclinical cerebrovascular disease.

Methods

This was a cross-sectional study involving 2012 North Chinese adults aged 40 and above. Serum Lp-PLA2 mass was measured using enzyme-linked immunosorbent assay (ELISA). Cerebral artery stenosis was assessed using two primary methods: transcranial Doppler (TCD) for intracranial artery stenosis (ICAS) and bilateral carotid duplex ultrasound for extracranial arterial stenosis (ECAS). Asymptomatic cerebral artery stenosis (ACAS) was defined as the presence of at least one of these stenoses. Statistical analyses, including logistic regression, were used to determine the association between Lp-PLA2 mass quartiles and the presence of ACAS, ICAS, and ECAS, while controlling for various vascular risk factors.

Datasets

The study utilized data from the Asymptomatic Polyvascular Abnormalities in Community (APAC) study, which included a random sample of 5440 participants aged ≥40 years from the Kailuan Study population. For this specific analysis, 2012 participants with complete demographic and blood sample information were selected. No new datasets were introduced.

Key Insights and Ideas

  • Lp-PLA2 as a potential early warning sign: The study strongly suggests that elevated Lp-PLA2 mass is not just associated with existing cardiovascular issues but can be an indicator of silent, developing problems like asymptomatic cerebral artery stenosis.
  • Sex and age matter: The association between Lp-PLA2 and ACAS was significantly stronger in men and older individuals. This highlights potential sex-specific or age-related differences in how Lp-PLA2 contributes to atherosclerosis.
  • Beyond inflammation: While Lp-PLA2 is known as an inflammatory marker, its consistent association with stenosis across different types (intracranial and extracranial) points to a broader role in the atherosclerotic process.
  • Biomarker potential: The findings support the idea that Lp-PLA2 mass could be a valuable, non-invasive tool to identify individuals who might be at higher risk for stroke, even before symptoms appear.

Key Results

The study found that participants in the highest quartile of Lp-PLA2 mass had a significantly increased risk of asymptomatic cerebral artery stenosis (ACAS). Specifically, the adjusted odds ratio (OR) for ACAS in the 4th quartile compared to the 1st quartile was 1.98 (95% CI: 1.42-2.78). This association remained significant for both intracranial (ICAS) and extracranial (ECAS) stenoses. The association was particularly pronounced in males (OR = 2.00) and older participants (aged ≥60 years, OR = 2.76 for ACAS in the highest quartile compared to the lowest, after stratification).

Limitations and Future Work

The authors acknowledge several limitations:

  • Diagnostic method: The reliance on TCD for ICAS diagnosis, rather than the gold standard of conventional angiography, might have included patients with non-atherosclerotic vascular pathology.
  • Sample storage: Blood samples were stored for 3-4 years at -80°C, which, while generally considered acceptable for Lp-PLA2 stability, could introduce some variability.
  • Cross-sectional design: This design limits the ability to establish a definitive cause-and-effect relationship between Lp-PLA2 mass and ACAS.
  • Study population: The majority of participants were coal workers, which may limit the generalizability of the findings to other populations.

Future work could involve longitudinal studies to confirm the predictive value of Lp-PLA2 for stroke events in individuals with ACAS. Further research is also needed to elucidate the sex-specific mechanisms underlying the observed associations and to explore the role of Lp-PLA2 in middle-aged populations.

Summary updated

Abstract

Cerebral artery stenosis (CAS) is the most important causes of ischaemic stroke. Lipoprotein-associated phospholipase A2 (Lp-PLA2) plays 2 diverse roles in atherosclerosis (pro-inflammatory and anti-inflammatory), and the association between Lp-PLA2 mass and cardiovascular or cerebrovascular events is inconsistent among previous studies. A cross-sectional study including 2012 North Chinese adults aged ≥40 years was performed in 2010-2011 to investigate whether Lp-PLA2 mass is associated with asymptomatic cerebral artery stenosis (ACAS). Serum Lp-PLA2 mass was determined by enzyme-linked immunosorbent assay (ELISA). All participants underwent transcranial Doppler (TCD) and bilateral carotid duplex ultrasound to evaluate intracranial artery stenosis (ICAS) and extracranial arterial stenosis (ECAS). The median serum Lp-PLA2 mass of the participants was 140.74 ng/mL (interquartile range: 131.79-158.07 ng/mL). The adjusted odds ratio (OR) when comparing the 4th quartile to the 1st quartile of Lp-PLA2 was 1.98 (95% confidence interval (CI): 1.42-2.78), 1.79 (95% CI: 1.08-2.94) and 1.87 (95% CI: 1.28-2.73) for the occurrence of ACAS, asymptomatic ECAS and asymptomatic ICAS, respectively, after controlling for vascular risk factors. These independently significant associations remained statistically significant in the male or elderly subgroups, but not in females or middle-aged participants. Lp-PLA2 mass is positively correlated with subclinical atherosclerosis determined by ACAS, ICAS and ECAS in North Chinese, particularly in male and older participants, suggesting that serum Lp-PLA2 mass might be potential biomarker for the detection of ACAS in the adults.
BibTeX
@article{wang2018association,
  author = {Youxin Wang and Bin Zhou and Pingan Zhou and Yan Yao and Qinghua Cui and Yingping Liu and Jichun Yang and Shouling Wu and Xingquan Zhao and Yong Zhou},
  title = {{Association of lipoprotein‐associated phospholipase A2 mass with asymptomatic cerebral artery stenosis}},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2018},
  doi = {10.1111/jcmm.13521},
}
Figure